Women at Risk for Breast Cancer Should Participate in Decisions About Risk-reducing Drugs
According to a draft recommendation recently introduced by the U.S. Preventive Services Task Force (USPSTF), physicians should strive to engage women at increased risk of breast cancer in the process of making decisions about medications that can reduce their risk. At-risk women who are deemed to be at low risk for adverse effects from these drugs could benefit from taking medications such as tamoxifen or raloxifene. (Source: AAFP Health of the Public)
Source: AAFP Health of the Public - April 16, 2013 Category: Primary Care Source Type: news
Chemoprevention for Women at High Risk for Breast CancerChemoprevention for Women at High Risk for Breast Cancer
The US Preventive Services Task Force has recommended the prophylactic use of tamoxifen and raloxifene in women at high risk for breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Discuss cancer-reducing drugs with women - panel
NEW YORK (Reuters Health) - Doctors should talk about breast cancer-reducing drugs with women and offer tamoxifen or raloxifene to those that have a high risk of cancer and aren't likely to suffer side effects, a government-backed panel said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Breast Cancer Drugs Urged for Healthy High-Risk Women
A panel of experts said tamoxifen and raloxifene may be worth taking to lower the risk of breast cancer despite the potential for serious side effects like blood clots and strokes. (Source: NYT Health)
Source: NYT Health - April 15, 2013 Category: Consumer Health News Authors: By DENISE GRADY Tags: Tamoxifen (Drug) Breast Cancer raloxifene United States Preventive Services Task Force Source Type: news
Chemoprevention of Breast Cancer: Evidence of Broad BenefitChemoprevention of Breast Cancer: Evidence of Broad Benefit
A systematic review of tamoxifen and raloxifene in the prevention of breast cancer will inform an upcoming update from the USPSTF. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Drugs to Avert Breast Cancer Not Always Used (CME/CE)
(MedPage Today) -- Drugs including tamoxifen and raloxifene are effective in reducing breast cancer incidence in high-risk women, but their side effects have discouraged use, a systematic review found. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 15, 2013 Category: Consumer Health News Source Type: news
NICE issues draft guideline on familial breast cancer for consultation
Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has published a draft guideline on the management of familial breast cancer, for consultation.
The draft guideline makes provisional recommendations on issues including - when to offer genetic testing, what surveillance strategies should and should not be offered, and the use of tamoxifen or raloxifene as treatments to prevent breast cancer.
The closing date for comments is 25 February 2013.
An embargoed version of the final guideline will be available to stakeholder organisations that com...
Source: NeLM - News - January 16, 2013 Category: Drugs & Pharmacology Source Type: news
Breast cancer drugs set for preventative use
Almost all of the newspapers and their websites are leading with the news that the National Institute for Health and Clinical Excellence (NICE) has published draft guidelines recommending that women with a high risk of familial breast cancer should be offered preventative drug treatments.
The news is based on draft guidelines released by NICE for the care of women at risk of developing breast cancer that runs in families (familial breast cancer).
The new draft guidelines update the 2006 guidelines, and include new recommendations on genetic testing and monitoring of the disease.
New proposals are also included for ...
Source: NHS News Feed - January 15, 2013 Category: Consumer Health News Tags: Cancer QA articles Source Type: news
NICE considers treatment for breast cancer prevention
A proposed update to the National Institute for Health and Clinical Excellence's familial breast cancer clinical guideline is exploring whether hormone therapy could be given to at-risk women for up to five years to help cut their risk of getting the disease.
According to the institute, for those for whom surgery is unsuitable, so-called 'chemoprevention' through drugs such as tamoxifen and raloxifene "may represent a more acceptable means of risk reduction", even though they are not licensed specifically for this use in the UK. (Source: NHS Networks)
Source: NHS Networks - January 15, 2013 Category: UK Health Authors: Maria Axford Source Type: news
